Read More

PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value

Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the

MYMD

Read More

Helius Medical Technologies’ PoNS Now Available On The VA Federal Supply Schedule And General Services Administration Advantage Contracts; PoNS System, Item # S1-001-02, Priced At $23,843.72 And The PoNS Mouthpiece, Item # M1-001, Priced At $7,344.97

-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential

HSDT